J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 7, Number 6, June 2015, pages 479-484

Effects of 6-Month Sitagliptin Treatment on Metabolic Parameters in Diabetic Patients Taking Oral Glucocorticoids: A Retrospective Cohort Study

Figure 1. (a) Correlation between changes in HbA1c after 6-month sitagliptin treatment and HbA1c levels at baseline. (b) Correlation between changes in HbA1c after 6-month sitagliptin treatment and daily glucocorticoids dose at baseline.

**Table 1.** Baseline Characteristics of Subjects Studied (n = 15)
Age	66.9 ± 13.9
Sex (M/F)	6/9
Body height (cm)	156 ± 11
Body weight (kg)	57.5 ± 11.4
Body mass index (BMI) (kg/m²)	23.5 ± 3.0
Diseases treated by glucocorticoids
Interstitial pneumonia	2 (13%)
Primary multiple myositis	2 (13%)
Polymyalgia rheumatica	2 (13%)
Dermatomyositis	1 (7%)
Rheumatoid arthritis	1 (7%)
Adult-onset Still’s disease	1 (7%)
Eosinophilic granulomatosis with polyangitis	1 (7%)
Sarcoidosis	1 (7%)
Panhypopituitarism	1 (7%)
Bullous pemphigoid	1 (7%)
Chronic urticaria	1 (7%)
Bronchial asthma	1 (7%)

Table 1. Baseline Characteristics of Subjects Studied (n = 15)

Age

66.9 ± 13.9

Sex (M/F)

6/9

Body height (cm)

156 ± 11

Body weight (kg)

57.5 ± 11.4

Body mass index (BMI) (kg/m²)

23.5 ± 3.0

Diseases treated by glucocorticoids

Interstitial pneumonia

2 (13%)

Primary multiple myositis

2 (13%)

Polymyalgia rheumatica

2 (13%)

Dermatomyositis

1 (7%)

Rheumatoid arthritis

1 (7%)

Adult-onset Still’s disease

1 (7%)

Eosinophilic granulomatosis with polyangitis

1 (7%)

Sarcoidosis

1 (7%)

Panhypopituitarism

1 (7%)

Bullous pemphigoid

1 (7%)

Chronic urticaria

1 (7%)

Bronchial asthma

1 (7%)

**Table 2.** Other Hypoglycemic Agents Which Subjects Had Taken Before and After the Treatment With Sitagliptin (n = 15)
Hypoglycemic agents	Pre-treatment	Post-treatment
None	6 (40%)	6 (40%)
Sulfonylureas	1 (7%)	4 (27%)
Biguanides	2 (13%)	4 (27%)
Thiazolidinediones	3 (20%)	3 (20%)
α-glucosidase inhibitors	5 (33%)	4 (27%)
Glinides	4 (27%)	0 (0%)
Insulin	1 (7%)	1 (7%)

Table 2. Other Hypoglycemic Agents Which Subjects Had Taken Before and After the Treatment With Sitagliptin (n = 15)

Hypoglycemic agents

Pre-treatment

Post-treatment

None

6 (40%)

Sulfonylureas

1 (7%)

4 (27%)

Biguanides

2 (13%)

4 (27%)

Thiazolidinediones

3 (20%)

α-glucosidase inhibitors

5 (33%)

4 (27%)

Glinides

4 (27%)

0 (0%)

Insulin

1 (7%)

**Table 3.** Changes in Variables After 6-Month Sitagliptin Treatment (n = 15)
	Subjects studied (n)	Pre-treatment	Post-treatment	P value
Body weight (kg)	9	61.6 (9.9)	58.9 (10.6)	0.001
Systolic blood pressure (mm Hg)	11	129 (18)	134 (17)	0.390
Diastolic blood pressure (mm Hg)	11	72 (10)	73 (16)	0.914
Plasma glucose (mg/dL)	15	195 (72)	121 (23)	0.004
HbA1c (%)	15	7.6 (0.9)	6.5 (0.9)	< 0.001
LDL-cholesterol (mg/dL)	9	107 (24)	100 (20)	0.079
Triglyceride (mg/dL)	11	133 (55)	163 (64)	0.228
HDL-cholesterol (mg/dL)	8	51 (16)	52 (14)	0.934
AST (IU/L)	14	30 (21)	26 (13)	0.508
ALT (IU/L)	14	32 (28)	24 (12)	0.302
γGTP (IU/L)	8	32 (12)	31 (21)	0.856
eGFR (mL/min/1.73m²)	14	86 (33)	80 (35)	0.029

Table 3. Changes in Variables After 6-Month Sitagliptin Treatment (n = 15)

Subjects studied (n)

Pre-treatment

Post-treatment

P value

Body weight (kg)

61.6 (9.9)

58.9 (10.6)

0.001

Systolic blood pressure (mm Hg)

129 (18)

134 (17)

0.390

Diastolic blood pressure (mm Hg)

72 (10)

73 (16)

0.914

Plasma glucose (mg/dL)

195 (72)

121 (23)

0.004

HbA1c (%)

7.6 (0.9)

6.5 (0.9)

< 0.001

LDL-cholesterol (mg/dL)

107 (24)

100 (20)

0.079

Triglyceride (mg/dL)

133 (55)

163 (64)

0.228

HDL-cholesterol (mg/dL)

51 (16)

52 (14)

0.934

AST (IU/L)

30 (21)

26 (13)

0.508

ALT (IU/L)

32 (28)

24 (12)

0.302

γGTP (IU/L)

32 (12)

31 (21)

0.856

eGFR (mL/min/1.73m²)

86 (33)

80 (35)

0.029

**Table 4.** Changes in Variables After 6-Month Sitagliptin Monotherapy (n = 5)
	Subjects studied (n)	Pre-treatment	Post-treatment	P value
Body weight (kg)	3	64.6 (3.6)	61.1 (2.5)	0.087
Systolic blood pressure (mm Hg)	4	126 (12)	133 (17)	0.568
Diastolic blood pressure (mm Hg)	4	75 (4)	83 (10)	0.345
Plasma glucose (mg/dL)	5	192 (76)	107 (22)	0.060
HbA1c (%)	5	7.0 (0.3)	5.9 (0.7)	0.036
LDL-cholesterol (mg/dL)	2	135 (4)	116 (18)	0.465
Triglyceride (mg/dL)	4	131 (44)	128 (36)	0.957
HDL-cholesterol (mg/dL)	3	59 (16)	48 (11)	0.148
AST (IU/L)	5	30 (16)	28 (19)	0.789
ALT (IU/L)	5	30 (17)	26 (14)	0.710
γGTP (IU/L)	3	39 (11)	35 (24)	0.789
eGFR (mL/min/1.73 m²)	5	111 (36)	108 (40)	0.486

Table 4. Changes in Variables After 6-Month Sitagliptin Monotherapy (n = 5)

Subjects studied (n)

Pre-treatment

Post-treatment

P value

Body weight (kg)

64.6 (3.6)

61.1 (2.5)

0.087

Systolic blood pressure (mm Hg)

126 (12)

133 (17)

0.568

Diastolic blood pressure (mm Hg)

75 (4)

83 (10)

0.345

Plasma glucose (mg/dL)

192 (76)

107 (22)

0.060

HbA1c (%)

7.0 (0.3)

5.9 (0.7)

0.036

LDL-cholesterol (mg/dL)

135 (4)

116 (18)

0.465

Triglyceride (mg/dL)

131 (44)

128 (36)

0.957

HDL-cholesterol (mg/dL)

59 (16)

48 (11)

0.148

AST (IU/L)

30 (16)

28 (19)

0.789

ALT (IU/L)

30 (17)

26 (14)

0.710

γGTP (IU/L)

39 (11)

35 (24)

0.789

eGFR (mL/min/1.73 m²)

111 (36)

108 (40)

0.486